Payment overview · 2025
General Payments
$456.32
15 reported records · 11 companies
Healthcare provider profile · identity verified
Janki Patel
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · UNION, NJ · NPI 1669129839
Verified facts
What the public records show
CMS Open Payments records show Janki Patel received $456.32 in general payments during 2025 across 15 reported records.
Napo Pharmaceuticals Inc accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $115.72 | 25.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.26 | 17.1% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $63.81 | 14.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.66 | 12.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.17 | 8.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.28 | 4.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.10 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.79 | 3.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.63 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.61 | 3.4% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $15.29 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $456.32 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $115.72 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $63.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.24 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $54.66 | 3 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $39.17 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 67 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carvedilol | Carvedilol | 451 | 215 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 226 |
| Losartan Potassium | Losartan Potassium | 368 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 134 |
| Warfarin Sodium | Warfarin Sodium | 198 | 32 |
| Furosemide | Furosemide | 156 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 52 |
| Eliquis | Apixaban | 106 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 55 |
| Simvastatin | Simvastatin | 86 | 47 |
| Metformin Hcl | Metformin Hcl | 84 | 51 |
| Farxiga | Dapagliflozin Propanediol | 69 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 38 |
| Lisinopril | Lisinopril | 56 | 29 |
| Metolazone | Metolazone | 53 | 30 |
| Gabapentin | Gabapentin | 49 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 18 |
| Omeprazole | Omeprazole | 36 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | 26 |
| Montelukast Sodium | Montelukast Sodium | 33 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 19 |
| Ezetimibe | Ezetimibe | 31 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 16 |
| Glipizide Er | Glipizide | 30 | 17 |
| Midodrine Hcl | Midodrine Hcl | 28 | 15 |
| Entresto | Sacubitril/Valsartan | 27 | 13 |
| Spironolactone | Spironolactone | 26 | 17 |
| Januvia | Sitagliptin Phosphate | 25 | 13 |
| Finasteride | Finasteride | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | 15 |
| Azithromycin | Azithromycin | 20 | 19 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 18 |
| Famotidine | Famotidine | 19 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 19 | 12 |
| Allopurinol | Allopurinol | 18 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 14 |
| Minoxidil | Minoxidil | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $456.32 · 15 records | Napo Pharmaceuticals Inc | ALVESCO, AURORA EV-ICD MRI SURESCAN, Cologuard Collection Kit, ELIQUIS, Kerendia, LEQVIO, LifeVest, Mytesi, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VERQUVO, Veltassa | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error